Mode
Text Size
Log in / Sign up

Thrombolysis plus endovascular therapy for basilar artery occlusion: a trial protocolNew trial plans to test stroke treatments for basilar artery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret with caution: this is a protocol; no efficacy or safety data are available yet.

This is a protocol for a multicenter randomized controlled trial conducted at approximately 100 hospitals in China. The study will enroll 340 patients with acute ischaemic stroke due to basilar artery occlusion (AIS-BAO) within 4.5 hours of onset. Participants will be randomized to receive either intravenous thrombolysis (IVT) plus endovascular treatment (EVT) or direct EVT alone. The primary outcome is the proportion of patients with independent neurological function, defined as a modified Rankin Scale score of 0 to 2 at 90±14 days after stroke onset. No results are reported as the study is ongoing. Safety outcomes, including adverse events and tolerability, are not yet available. Key limitations include the lack of results; the protocol only describes the planned methodology. The trial aims to provide evidence on whether adding IVT before EVT improves outcomes compared to EVT alone in this specific patient population. Clinicians should await the final results before considering changes to practice.

When someone suffers an ischemic stroke caused by a blockage in the basilar artery, every minute counts. This specific type of stroke can be very serious because it affects a major blood vessel in the brain. Doctors are looking for the best way to treat these patients quickly.

A new trial involving 340 patients will compare two different treatment paths. One group will receive both an intravenous clot-busting drug and a procedure to physically remove the blockage. The other group will receive only the procedure. The goal is to see if adding the medication helps more people regain independent function after the stroke.

Because this is a study protocol, the final results are not yet available. The researchers are still in the planning and early stages of the trial across 100 hospitals. While we cannot know the outcome yet, the study aims to provide clear evidence on whether combining these two treatments is better than using just one.

What this means for you:
A new large-scale trial will test if adding clot-busting drugs improves outcomes for a specific type of stroke.

Common questions

What specific type of stroke is being studied?

The study focuses on patients who have an ischemic stroke caused by a blockage in the basilar artery. This occurs when someone has a stroke within 4.5 hours of it starting.

How will the two treatment groups be different?

One group will receive both intravenous thrombolysis (a clot-busting drug) and endovascular treatment (a procedure to remove the blockage). The other group will receive only the endovascular treatment.

Are the results of this study available yet?

No, the results are not available yet. This document is a study protocol, which means it is the plan for the trial. The researchers have not yet finished the study or reported any findings.

Study Details

Study typeRct
Sample sizen = 340
EvidenceLevel 2
PublishedJun 2026
View Original Abstract ↓
BACKGROUND: Endovascular treatment (EVT) is safe and effective in treating acute ischaemic stroke due to basilar artery occlusion (AIS-BAO); nonetheless, the impact of intravenous thrombolysis (IVT) on its efficacy remains unclear. OBJECTIVE: To compare the effectiveness and safety of EVT with or without prior IVT in treating AIS-BAO patients within 4.5 hours after stroke onset. METHODS AND DESIGN: A multicentre, prospective, randomised, open-label controlled clinical trial with blinded assessment of endpoints. 340 patients will be consecutively randomised to receive IVT plus EVT or direct EVT in a ratio of 1:1 from about 100 hospitals in China. An interim analysis is planned when one-third (114) of the patients have completed the primary endpoint follow-ups. It anticipates that IVT plus EVT demonstrates superiority over direct EVT. If the superiority of IVT plus EVT over direct EVT is less than expected, the sample size may be expanded by up to 20% of the original size. If the efficacy of the two groups is similar, it will shift to a non-inferiority hypothesis, aiming to evaluate whether direct EVT is non-inferior to IVT plus EVT. OUTCOME: The primary endpoint is the proportion of independent neurological function defined as a modified Rankin Scale score of 0 to 2 at 90±14 days after stroke onset. DISCUSSION: This trial is expected to provide novel evidence of the superiority or non-inferiority between EVT with or without IVT in the treatment of patients with AIS-BAO. TRIAL REGISTRATION: NCT05631847 at ClinicalTrials.gov and ChiCTR2300070584 at Chictr.org.cn.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.